Skip to main content

Table 3 Adverse events

From: A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

 

MiRI

SRI

 

Edoxaban 30 mg

Edoxaban 15 mg

Fondaparinux 1.5 mg

CL CR mL/min

≥50 to ≤80

≥15 to <30

≥15 to <20

≥20 to <30

≥20 to <30

N

30

29 (total)

7

22

20

Adverse events

n (%)

22 (73.3)

18 (62.1)

6 (85.7)

12 (54.5)

12 (60.0)

95% CI a

55.6, 85.8

44.0, 77.3

48.7, 97.4

34.7, 73.1

38.7, 78.1

MedDRA preferred term, reported by ≥2 patients, n (%)

Alanine aminotransferase increased

2 (6.7)

3 (10.3)

1 (14.3)

2 (9.1)

0 (0.0)

Aspartate aminotransferase increased

1 (3.3)

5 (17.2)

2 (28.6)

3 (13.6)

0 (0.0)

Blood alkaline phosphatase increased

0 (0.0)

6 (20.7)

1 (14.3)

5 (22.7)

0 (0.0)

Blood bilirubin increased

2 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Blood lactate dehydrogenase increased

0 (0.0)

2 (6.9)

1 (14.3)

1 (4.5)

0 (0.0)

Blood urine present

4 (13.3)

2 (6.9)

0 (0.0)

2 (9.1)

1 (5.0)

Cystitis

2 (6.7)

5 (17.2)

2 (28.6)

3 (13.6)

1 (5.0)

Gamma-glutamyltransferase increased

5 (16.7)

6 (20.7)

2 (28.6)

4 (18.2)

0 (0.0)

Hemorrhage subcutaneous

6 (20.0)

1 (3.4)

0 (0.0)

1 (4.5)

3 (15.0)

Hemoglobin decreased

0 (0.0)

1 (3.4)

1 (14.3)

0 (0.0)

3 (15.0)

Nasopharyngitis

0 (0.0)

2 (6.9)

0 (0.0)

2 (9.1)

1 (5.0)

Red blood cells urine positive

2 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Subcutaneous hematoma

1 (3.3)

3 (10.3)

1 (14.3)

2 (9.1)

0 (0.0)

Urinary tract infection

2 (6.7)

1 (3.4)

0 (0.0)

1 (4.5)

2 (10.0)

Adverse drug reactions

n (%)

13 (43.3)

7 (24.1)

1 (14.3)

6 (27.3)

6 (30.0)

95% CI a

27.4, 60.8

12.2, 42.1

2.6, 51.3

13.2, 48.2

14.5, 51.9

Serious adverse events

n (%)

1 (3.3)

5 (17.2)

3 (42.9)

2 (9.1)

3 (15.0)

95% CI a

0.6, 16.7

7.6, 34.5

15.8, 75.0

2.5, 27.8

5.2, 36.0

Adverse events leading to treatment discontinuation

n (%)

0

2 (6.9)

0

2 (9.1)

1 (5.0)

95% CI a

0.0, 11.4

1.9, 22.0

0.0, 35.4

2.5, 27.8

0.9, 23.6

  1. CI = confidence interval; CLCR = creatinine clearance; MedDRA = medical dictionary for regulatory activities; MiRI = mild renal impairment; SRI = severe renal impairment.
  2. aScore method.